Aktionsplan CalciMedica, Inc.
Erweiterter Zeitplan
Einfaches Diagramm
Über das Unternehmen CalciMedica, Inc.
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. weitere detailsIPO date | 2020-09-25 |
---|---|
ISIN | US38942Q2021 |
Industry | Biotechnology |
Sector | Health Care |
Валюта | usd |
Валюта отчета | usd |
Сайт | https://www.calcimedica.com |
Цена ао | 1.99 |
Preisänderung pro Tag: | -3.86% (2.07) |
---|---|
Preisänderung pro Woche: | -0.995% (2.01) |
Preisänderung pro Monat: | -13.85% (2.31) |
Preisänderung über 3 Monate: | -30.18% (2.85) |
Preisänderung über sechs Monate: | -55.08% (4.43) |
Preisänderung pro Jahr: | -52.16% (4.16) |
Preisänderung über 3 Jahre: | +48.51% (1.34) |
Preisänderung seit Jahresbeginn: | -39.51% (3.29) |
|
Unterschätzung
|
Effizienz
|
|||||||||||||||||||||||||||||||||||||
Dividenden
|
Pflicht
|
Wachstumsimpuls
|
Institutionen | Volumen | Aktie, % |
---|---|---|
Orbimed Advisors LLC. | 297380 | 5.25 |
Bml Capital Management, LLC | 145424 | 2.57 |
Meritage Portfolio Management | 46000 | 0.81 |
Geode Capital Management, LLC | 13354 | 0.24 |
First Manhattan Company | 13226 | 0.23 |
Tower Research Capital LLC (TRC) | 1417 | 0.03 |
Morgan Stanley | 856 | 0.02 |
Bank of America Corporation | 507 | 0.01 |
Wells Fargo & Company | 16 | 0 |
Cutler Group LP | 14 | 0 |
ETF | Aktie, % | Rentabilität für das Jahr, % | Dividenden, % |
---|---|---|---|
iShares Micro-Cap ETF | 0.00805 | 17.09 | 1.54048 |
0.01 | 17.09 | 1.54 |
Aufsicht | Berufsbezeichnung | Zahlung | Geburtsjahr |
---|---|---|---|
Dr. A. Rachel Leheny Ph.D. | CEO & Director | 852.84k | 1963 (62 Jahr) |
Mr. Eric W. Roberts | Chief Business Officer & Vice Chairman of the Board | 757.4k | 1964 (61 Jahr) |
Dr. Anjana Rao Ph.D. | Co-Founder and Scientific Advisor | N/A | |
Dr. Patrick Hogan Ph.D. | Co-Founder and Scientific Advisor | N/A | |
Dr. Stefan Feske M.D. | Co-Founder and Scientific Advisor | N/A | |
Dr. Kenneth A. Stauderman Ph.D. | Co-Founder & Chief Scientific Officer | 615.59k | 1953 (72 Jahr) |
Mr. Daniel E. Geffken M.B.A. | Interim Chief Financial Officer | N/A | 1957 (68 Jahre) |
Mr. John M. Dunn J.D. | General Counsel | N/A | 1952 (73 Jahr) |
Mr. Michael J. Dunn M.B.A., MBA | President & COO | N/A | 1956 (69 Jahre) |
Dr. Sudarshan Hebbar M.D. | Chief Medical Officer | 1965 (60 Jahre) |
Adresse: United States, La Jolla. CA, 505 Coast Boulevard South - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.calcimedica.com
Webseite: https://www.calcimedica.com